These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8573479)

  • 1. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
    Lamm DL
    Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing progression and improving survival with BCG maintenance.
    Lamm DL
    Eur Urol; 2000; 37 Suppl 1():9-15. PubMed ID: 10575266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
    Lamm DL
    Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L; Csizer Z; Sparkes JD
    Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
    De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
    Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 9. Carcinoma in situ.
    Lamm DL
    Urol Clin North Am; 1992 Aug; 19(3):499-508. PubMed ID: 1636234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
    Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal BCG treatment of superficial bladder cancer as defined by American trials.
    Lamm DL
    Eur Urol; 1992; 21 Suppl 2():12-6. PubMed ID: 1396941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of intravesical chemotherapy and immunotherapy.
    Sarosdy MF
    Urol Clin North Am; 1992 Aug; 19(3):509-19. PubMed ID: 1636235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.